Compare MBI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | ZNTL |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.7M | 289.0M |
| IPO Year | 1994 | 2020 |
| Metric | MBI | ZNTL |
|---|---|---|
| Price | $6.51 | $4.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.00 | $6.60 |
| AVG Volume (30 Days) | 310.0K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.04 | 18.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 90.48 | N/A |
| 52 Week Low | $4.41 | $1.21 |
| 52 Week High | $8.26 | $6.95 |
| Indicator | MBI | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 64.59 |
| Support Level | $6.42 | $3.53 |
| Resistance Level | $6.94 | $5.11 |
| Average True Range (ATR) | 0.24 | 0.38 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 65.50 | 81.88 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. The U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiaries.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.